A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

NCT04306042 · clinicaltrials.gov ↗

UNKNOWN

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Lung Squamous Cell Carcinoma Stage IV

Interventions

DRUG: Nivolumab or Pembrolizumab

Sponsor

Guangdong Association of Clinical Trials